ASTar is a fully automatic system for antibiotic susceptibility testing (AST) with little hands-on time, ease-of-use and capabilities to deliver a broad answer within approximately six hours for positive blood cultures.

This order aims to enable commercial readiness for the first customer orders after launch. Commercial launch can take place as soon as the clinical study is finalized and ASTar is CE-IVD approved. ASTar´s first application is focused on improving the diagnostics for patients with blood stream infections, where sepsis is the most common condition.

The value of the first order from Thermo Fisher Scientific exceeds SEK 8 million. The structure of the order also includes a pre-payment for a binding order for the next six months.

Both Thermo Fisher Scientific and Q-linea believe in a strong growth for ASTar and aim for a long term successful and strong ramp-up after the first controlled launch phase.

“We are of course very excited to see the first order coming in before the completion of the clinical study. This enables us together to be ready for launch and shows the trust our partner has in a successful outcome of the clinical study. I also think that the structure with binding orders and pre-payment is important as we move into the commercial phase for Q-linea,” said Jonas Jarvius, CEO of Q-linea.